CABA - Cabaletta Bio, Inc.

QQQ $ 435.98 $ 8.58 (2.01 %)

DIA $ 386.87 $ 4.54 (1.19 %)

SPY $ 511.25 $ 6.26 (1.24 %)

TLT $ 89.88 $ 0.90 (1.01 %)

GLD $ 212.97 $ -0.17 (-0.08 %)

Previous Close

$ 12.39

Open

$ 12.95

Bid

$ 0.00 x 0

Ask

$ 0.00 x 0

Day's Range

$ 12.20 - $ 12.95

52 Week Range

$ 9.02 - $ 26.35

Volume

817,190

Average Volume

Market Cap

597.71M

Beta (5Y Monthly)

$ 1.54

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	03-21-2024	12-31-2023	10-K
2	11-09-2023	09-30-2023	10-Q
3	08-10-2023	06-30-2023	10-Q
4	05-11-2023	03-31-2023	10-Q
5	03-16-2023	12-31-2022	10-K
6	11-10-2022	09-30-2022	10-Q
7	08-11-2022	06-30-2022	10-Q
8	05-12-2022	03-31-2022	10-Q
9	03-17-2022	12-31-2021	10-K
10	11-01-2021	09-30-2021	10-Q
11	08-05-2021	06-30-2021	10-Q
12	05-03-2021	03-31-2021	10-Q
13	03-16-2021	12-31-2020	10-K
14	11-10-2020	09-30-2020	10-Q
15	08-06-2020	06-30-2020	10-Q
16	05-12-2020	03-31-2020	10-Q
17	03-30-2020	12-31-2019	10-K
18	12-05-2019	09-30-2019	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Cantor Fitzgerald Reiterates Overweight on...
04/05/2024 13:19:03

Cantor Fitzgerald analyst Joshua Schimmer reiterates Cabaletta Bio (NASDAQ:CABA) with a Overweight and maintains $50 price t...

Citigroup Maintains Buy on Cabaletta Bio, ...
04/04/2024 15:47:06

Citigroup analyst Samantha Semenkow maintains Cabaletta Bio (NASDAQ:CABA) with a Buy and raises the price target from $26 to...

Cabaletta Bio Issued ID#NCT06328777 For Ph...
03/25/2024 14:25:25

https://clinicaltrials.gov/study/NCT06328777 Inclusion Criteria:

Cantor Fitzgerald Reiterates Overweight on...
03/22/2024 17:54:33

Cantor Fitzgerald analyst Joshua Schimmer reiterates Cabaletta Bio (NASDAQ:CABA) with a Overweight and maintains $50 price t...

Wells Fargo Maintains Overweight on Cabale...
03/22/2024 17:40:24

Wells Fargo analyst Derek Archila maintains Cabaletta Bio (NASDAQ:CABA) with a Overweight and raises the price target from $...

HC Wainwright & Co. Maintains Buy on Cabal...
03/22/2024 14:55:45

HC Wainwright & Co. analyst Douglas Tsao maintains Cabaletta Bio (NASDAQ:CABA) with a Buy and raises the price target fr...

Recap: Cabaletta Bio Q4 Earnings
03/21/2024 13:10:06

Cabaletta Bio Inc Files For Mixed Shelf Of...
03/21/2024 12:05:33

- SEC Filing

Cabaletta Bio Q4 EPS $(0.46) Misses $(0.39...
03/21/2024 11:22:50

Cabaletta Bio (NASDAQ:CABA) reported quarterly losses of $(0.46) per share which missed the analyst consensus estimate of $(0.3...

FDA Granted Orphan Drug Designation To Cab...
03/20/2024 11:03:04

cramer-this-reit-is-a-little-too-dicey-as-for-marathon-digital-own-the-pure

Cramer: This REIT Is 'A Little Too Dicey';...
03/06/2024 14:20:57

On CNBC’s "Mad Money Lightning Round," Jim Cramer recommended holding onto Regions Financial Corporation (NYSE: RF).

Jefferies Initiates Coverage On Cabaletta ...
02/05/2024 11:00:06

Jefferies analyst Kelly Shi initiates coverage on Cabaletta Bio (NASDAQ:CABA) with a Buy rating and announces Price Target o...

Cabaletta Bio Announces FDA Granted Orphan...
02/01/2024 21:40:43

12-health-care-stocks-moving-in-mondays-after-market-session

12 Health Care Stocks Moving In Monday's A...
01/22/2024 21:31:12

Cabaletta Bio Gets Additional FDA Fast Tra...
01/08/2024 12:05:40

To date, Cabaletta has received clearance from the FDA for Investigational New Drug (IND) applications for CABA-201 in multiple...

verint-reports-strong-earnings-joins-semtech-alphabet-and-other-big-stocks-moving-higher-on-thursday

Verint Reports Strong Earnings, Joins Semt...
12/07/2023 15:17:42

U.S. stocks traded mostly higher, with the Nasdaq Composite gaining more than 100 points on Thursday.

Morgan Stanley Maintains Overweight on Cab...
11/29/2023 15:02:25

Morgan Stanley analyst Michael Ulz maintains Cabaletta Bio (NASDAQ:CABA) with a Overweight and lowers the price target from ...

Analyst Ratings for Cabaletta Bio
11/29/2023 12:00:31

HC Wainwright & Co. Reiterates Buy on Caba...
11/29/2023 11:14:48

HC Wainwright & Co. analyst Douglas Tsao reiterates Cabaletta Bio (NASDAQ:CABA) with a Buy and maintains $25 price target.

Leslie's Posts Weak Earnings, Joins Las Ve...
11/29/2023 10:48:40

U.S. stock futures traded higher this morning, with the Dow Jones futures gaining around 100 points on Wednesday.